Farmaseuttisen kemian laitos
Department of Pharmaceutical Chemistry

Julkaisut 2003
Publications 2003

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Asikainen A et al. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes.
2 Forsberg M et al. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
3 Fowler CJ et al. Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid.
4 Heimbach T et al. Absorption rate limit considerations for oral phosphate prodrugs.
5 Juntunen J et al. Anandamide prodrugs: 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide.
6 Juntunen J et al. Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether.
7 Jyrkkärinne J et al. Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.
8 Järvinen T. Farmasian osaajat - on aika mennä lääkealan eturintamaan!
9 Järvinen T. Farmaseuttinen lääketutkimuskeskus - silta yliopistotutkimuksesta elinkeinoelämään.
10 Järvinen T et al., keksijä. Uudet metyloidut syklodekstriininkompleksit.
11 Järvinen T et al., keksijä. Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen aihiolääkkeitä sisältävät farmaseuttiset koostumukset topikaaliseen käyttöön.
12 Kinnarinen T et al. Pulmonary deposition of a budesonide/gamma-cyclodextrin complex in vitro.
13 Kostiainen R et al. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies.
14 Laine K et al. Topically administered CB2-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits.
15 Leppänen J. Aihiolääkkeitä Parkinsonin taudin hoitoon.
16 Mayer PT et al. A hydrophobicity scale for the lipid bilayer barrier domain from peptide permeabilities: nonadditivities in residue contributions.
17 Mönkkönen H et al. Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: a possible correlation with bisphosphonate-induced gastrointestinal side-effects.
18 Rahnasto M et al. More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde.
19 Savinainen JR et al. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
20 Savolainen J et al. A novel D2-dopaminergic and alfa2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits.
21 Tengvall U et al. Characterization of antisense oligonucleotide-peptide conjugates with negative ionization electrospray mass spectrometry and liquid chromatography-mass spectrometry.
22 Tervo AJ et al. A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods.
23 Tolle-Sander S et al. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.
24 Toropainen E et al. Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model.
25 Turhanen PA et al. First synthesis of etidronate partial amides starting from PCI3.
26 Wallén EAA. Design and Synthesis of Novel Prolyl Oligopeptidase Inhibitors.
27 Wallén EAA et al. Addition of tert-butylcuprate to (2S)-N-acyl-delta5-dehydroprolinates as a diastereoselective synthetic procedure for obtaining (2S,5S)-5-tert-butylproline.
28 Wallén EAA et al. New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(L-prolyl-pyrrolidine) amides.
29 Wallén EAA et al. Conformationally rigid N-Acyl-5-alkyl-L-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors.
30 Xiang T-X et al. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.

Farmaseuttisen kemian laitos Department of Pharmaceutical Chemistry
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008